Randomized trial of medical treatment versus hysterectomy for abnormal uterine bleeding: Resource use in the Medicine or Surgery (Ms) trial
| Autor: | Jonathan Showstack, Robert L. Summitt, Miriam Kuppermann, Lee A. Learman, Eric Vittinghoff, Feng Lin, Stephen B. Hulley, S. Gene McNeeley, Holly E. Richter, A. Eugene Washington, R. Edward Varner |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
medicine.medical_specialty medicine.medical_treatment MEDLINE Hysterectomy law.invention Randomized controlled trial Quality of life Pregnancy law Humans Medicine Medroxyprogesterone acetate Menorrhagia Diagnosis-Related Groups Hysterectomy procedure business.industry Obstetrics and Gynecology Middle Aged Relative Value Scales medicine.disease United States Surgery Clinical trial Treatment Outcome Quality of Life Health Resources Female business medicine.drug |
| Zdroj: | American Journal of Obstetrics and Gynecology. 194:332-338 |
| ISSN: | 0002-9378 |
| DOI: | 10.1016/j.ajog.2005.08.014 |
| Popis: | Objective This study was undertaken to compare resource use outcomes for participants in the Medicine or Surgery (Ms) randomized trial. Study design In a randomized controlled trial, we compared resources used during a 24-month follow-up period by women with abnormal uterine bleeding who were randomly assigned to either expanded medical treatment or hysterectomy. Results Women randomly assigned to hysterectomy used significantly more resources (medicine = $4479, hysterectomy=$6777; P = .03), with almost all the difference caused by the hysterectomy procedure. Fifty-three percent of women randomly assigned to medicine had a hysterectomy during the follow-up period; women who were able to continue on medical therapy had mean total resource use of $2595 compared with $6128 for medicine patients who eventually had surgery. Conclusion For women with abnormal uterine bleeding refractory to cyclic medroxyprogesterone acetate, compared with expanded medical treatment, hysterectomy increases resource use significantly and results in better clinical and 6-month quality-of-life outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect